Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 th immunorad conference
Year: 2024
Type: article
Abstract: Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer. Herein, we report on the topics developed by key-opinion leaders during the 7th Immunorad Conference held in Paris-Les Cordeliers (France) from September 27th to 29th 2023, and set the stage for the 8th edition of Immunorad which will be held at Weill Cornell Medical College (New-York, USA) in October 2024.
Source: OncoImmunology
Authors: Pierre-Antoine Laurent, Fabrice André, Alexandre Bobard, Desiree Deandreis, Sandra Demaria, Stephane Depil, Stefan B. Eichmüller, Cristian Fernandez-Palomo, Floris Foijer, Lorenzo Galluzzi, Jérôme Galon, Matthias Guckenberger, Kevin J. Harrington, Fernanda G. Herrera, Peter E. Huber, Antoine Italiano, Sana D. Karam, Guido Kroemer, Philippe Lambin, Carola Leuschner, Alberto Mantovani, Etienne Meylan, Michele Mondini, Mikael J. Pittet, Jean-Pierre Pouget, Jordi Remon, Claus S. Sørensen, Christos Sotiriou, Claire Vanpouille-Box, Ralph R. Weichselbaum, James W. Welsh, Laurence Zitvogel, Silvia C. Formenti, Eric Deutsch
Institutions: Inserm, Institut Gustave Roussy, Fondation Gustave Roussy, Weill Cornell Medicine, Lyon 1 Université, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, German Cancer Research Center, University of Bern, University Medical Center Groningen, University of Groningen, Université Paris Cité, Sorbonne Université, Sorbonne Paris Cité, Centre de Recherche des Cordeliers, Laboratoire d’immunologie intégrative du cancer, University Hospital Zurich, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, NIHR Biomedical Research Centre at The Royal Marsden and the ICR, Centre Hospitalier Universitaire Vaudois, Ludwig Cancer Research, University of Lausanne, Heidelberg University, University Hospital Heidelberg, Heidelberger Institut für Radioonkologie, Université de Bordeaux, Institut Bergonié, University of Colorado Anschutz, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Maastricht University Medical Centre, Maastricht University, The University of Texas MD Anderson Cancer Center, Queen Mary University of London, William Harvey Research Institute, IRCCS Humanitas Research Hospital, Université Libre de Bruxelles, Institut Jules Bordet, University of Geneva, University Hospital of Geneva, Swiss Cancer Center Léman, Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier, Institut Regional du Cancer de Montpellier, University of Copenhagen, University of Chicago, Université Paris-Saclay, Immunologie anti-tumorale et immunothérapie des cancers
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,913
Awards: G1260320607, Tackling the Achilles Heel of Immunotherapy: Validating imaging biomarkers and targeting the immunological niche of tumour hypoxia, Optimal treatment for patients with solid tumours in Europe through Artificial intelligence, G4533209236, A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology, Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer, G5810721675, G588901241, The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics, Accelerating the lab to market transition of AI tools for cancer management, International Clinical Validation of Radiomics Artificial Intelligence for Breast Cancer Treatment Planning, G7770515289, AI powered Data Curation & Publishing Virtual Assistant, Real-world-data Enabled Assessment for heaLth regulatory decision-Making
OpenAlex ID: W4405603329